Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Timolol
Drug ID BADD_D02219
Description Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes.[L6724] It is also used in tablet form as a drug to treat hypertension.[L6727] Timolol was first approved by the FDA in 1978.[L6724] This drug is marketed by several manufacturers [L6736] and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.
Indications and Usage In its oral form it is used to treat high blood pressure and prevent heart attacks, and occasionally to prevent migraine headaches. In its opthalmic form it is used to treat open-angle and occasionally secondary glaucoma.
Marketing Status Prescription; Discontinued
ATC Code C07AA06; S01ED01
DrugBank ID DB00373
KEGG ID D00378
MeSH ID D013999
PubChem ID 33624
TTD Drug ID D05UVD
NDC Product Code 17478-365; 76478-002; 17478-366; 76478-001; 17478-189
Synonyms Timolol | Timolol Maleate | Timolol Maleate, (1:1) Salt | (S)-1-((1,1-Dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadazol-3-yl)oxy)-2-propanol | 2-Propanol, 1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-, (S)- | Timoptic | Timoptol | Timacar | Timolol Hemihydrate | Blocadren | L-714,465 | L 714,465 | L714,465 | MK-950 | MK 950 | MK950 | Optimol
Chemical Information
Molecular Formula C13H24N4O3S
CAS Registry Number 26839-75-8
SMILES CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionCytochrome P450 2D6P10635T57392Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Foreign body sensation in eyes06.01.01.0060.000439%Not Available
Conjunctival hyperaemia06.04.01.0040.000439%Not Available
Haemodynamic instability24.03.02.0060.000439%Not Available
Eyelid margin crusting23.03.03.029; 06.04.04.0050.001317%Not Available
Eye pruritus06.04.05.0060.000658%Not Available
Ocular discomfort06.08.03.0080.000439%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Affect lability19.04.01.001--Not Available
Purpura non-thrombocytopenic01.01.04.006--Not Available
Cystoid macular oedema12.02.02.005; 06.04.06.010--Not Available
Serositis08.01.05.006--Not Available
Dermatitis psoriasiform23.03.14.004--Not Available
Vasodilation procedure25.03.01.001--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Angiopathy24.03.02.007--Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.01.01.003--Not Available
Connective tissue disorder15.06.01.006--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Sensation of foreign body08.01.09.002--Not Available
Respiratory tract infection22.07.07.001; 11.01.08.017--Not Available
Arterial insufficiency24.04.02.005--Not Available
Oropharyngeal discomfort22.02.05.027; 07.05.05.008--Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.004--
Acute kidney injury20.01.03.0160.000439%
Device capturing issue27.01.02.001--Not Available
The 7th Page    First    Pre   7 8    Next   Last    Total 8 Pages